Alkem Laboratories Limited
Goldman Sachs bought 48,090 shares of Alkem Laboratories for ₹25.01 Cr at ₹5200.00 apiece in a block deal.
A pharmaceutical company engaged in the development, manufacture, and sale of drugs and nutraceutical products across global markets. The company operates research-driven facilities to serve both domestic and international customers with a focus on therapeutic innovation. Its distinctive approach combines pharmaceutical manufacturing expertise with nutraceutical offerings to address diverse healthcare needs and patient populations worldwide.
US-based global investment bank (USD 1.6 trillion in assets, USD 3 trillion+ in client AUM through Goldman Sachs Asset Management). India FPI activity covers proprietary, market-making, client flows and active asset management mandates in listed Indian equities.